GlassScriptPhysician profile
Syed Rehman
NPI 1891778296
$7,265.94
in general payments reported to CMS, 2019-2025
43 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $402 · 2021: $318 · 2022: $1,190 · 2023: $1,390 · 2024: $1,425 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,106.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $817.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $603.74 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $495.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $379.12 | 2019-2025 | |
| Amgen INC. | $323.49 | 2019-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $275.60 | 2022-2025 | |
| Shield Therapeutics INC | $176.56 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $157.45 | 2019-2024 | Steglatro, Belsomra, Gardasil 9 |
| Exact Sciences Corporation | $145.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.36 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.13 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $110.82 | 2019-2021 | |
| Viatris Specialty LLC | $98.50 | 2025 | Yupelri |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.